Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AEON AEON Biopharma	$0.77 -1.5%	$0.79	$0.38 ▼ $115.57	$8.68M	0.71	1.68 million shs	105,344 shs
AKBA Akebia Therapeutics	$3.25 -1.2%	$3.66	$1.24 ▼ $4.08	$872.33M	0.96	3.95 million shs	3.70 million shs
ANL Adlai Nortye	$1.69 -3.4%	$1.55	$1.10 ▼ $3.89	$64.57M	-0.95	5,579 shs	57,939 shs
SIGA Siga Technologies	$8.50 -0.9%	$6.96	$4.95 ▼ $11.91	$614.38M	0.94	591,319 shs	466,389 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AEON AEON Biopharma	-1.54%	+9.25%	-0.90%	+53.60%	-98.94%
AKBA Akebia Therapeutics	-1.22%	-4.97%	-16.67%	+24.52%	+140.74%
ANL Adlai Nortye	-3.98%	+7.30%	+11.55%	-15.08%	-48.79%
SIGA Siga Technologies	-0.93%	-5.13%	+25.37%	+41.90%	-28.99%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AEON AEON Biopharma	3.4483 of 5 stars	3.5	5.0	0.0	0.6	1.7	1.9
AKBA Akebia Therapeutics	3.9709 of 5 stars	3.6	2.0	4.0	2.6	0.8	0.6
ANL Adlai Nortye	1.3663 of 5 stars	3.0	3.0	0.0	1.8	0.0	0.0
SIGA Siga Technologies	2.1256 of 5 stars	0.0	2.0	0.0	2.6	0.8	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AEON AEON Biopharma	3.00	Buy	$360.00	46,775.00% Upside
AKBA Akebia Therapeutics	3.20	Buy	$6.75	107.69% Upside
ANL Adlai Nortye	2.00	Hold	$9.00	432.54% Upside
SIGA Siga Technologies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ANL, AKBA, SIGA, and AEON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
6/2/2025	ANL Adlai Nortye	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AEON AEON Biopharma	N/A	N/A	N/A	N/A	($4.12) per share	N/A
AKBA Akebia Therapeutics	$203.73M	4.23	N/A	N/A	$0.11 per share	29.55
ANL Adlai Nortye	$5M	12.47	N/A	N/A	$0.69 per share	2.45
SIGA Siga Technologies	$138.72M	4.39	$0.83 per share	10.25	$2.92 per share	2.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AEON AEON Biopharma	-$36.63M	-$6.08	4.27	N/A	N/A	N/A	N/A	-994.63%	N/A
AKBA Akebia Therapeutics	-$69.41M	-$0.17	N/A	N/A	N/A	-17.91%	N/A	-13.47%	N/A
ANL Adlai Nortye	-$51.87M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	$59.21M	$1.13	7.52	6.80	N/A	45.73%	40.52%	35.62%	N/A

Latest ANL, AKBA, SIGA, and AEON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/5/2025	Q2 2025	SIGA Siga Technologies	N/A	$0.49	N/A	$0.49	N/A	$81.12 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AEON AEON Biopharma	N/A	N/A	N/A	N/A	N/A
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
ANL Adlai Nortye	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AEON AEON Biopharma	N/A	0.22	0.22
AKBA Akebia Therapeutics	1.61	1.98	1.84
ANL Adlai Nortye	0.02	1.41	1.41
SIGA Siga Technologies	N/A	10.09	8.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AEON AEON Biopharma	22.78%
AKBA Akebia Therapeutics	33.92%
ANL Adlai Nortye	35.21%
SIGA Siga Technologies	55.40%

Insider Ownership

Company	Insider Ownership
AEON AEON Biopharma	0.86%
AKBA Akebia Therapeutics	3.00%
ANL Adlai Nortye	N/A
SIGA Siga Technologies	1.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AEON AEON Biopharma	5	11.31 million	74.37 million	Not Optionable
AKBA Akebia Therapeutics	430	265.15 million	257.19 million	Optionable
ANL Adlai Nortye	127	36.90 million	N/A	Not Optionable
SIGA Siga Technologies	40	71.61 million	70.21 million	Optionable

ANL, AKBA, SIGA, and AEON Headlines

Recent News About These Companies

Siga Technologies (NASDAQ:SIGA) Trading Down 4.9% - Should You Sell?

August 15 at 6:20 PM | marketbeat.com

Siga Technologies (NASDAQ:SIGA) Rating Increased to Strong-Buy at Wall Street Zen

August 11, 2025 | americanbankingnews.com

Wall Street Zen Upgrades Siga Technologies (NASDAQ:SIGA) to Strong-Buy

August 10, 2025 | marketbeat.com

SIGA Technologies Second Quarter 2025 Earnings: EPS: US$0.50 (vs US$0.026 in 2Q 2024)

August 8, 2025 | finance.yahoo.com

Siga Technologies (NASDAQ:SIGA) Trading 13.9% Higher - Here's Why

August 7, 2025 | marketbeat.com

SIGA (SIGA) Q2 Revenue Soars 272%

August 7, 2025 | theglobeandmail.com

Siga Technologies Sees Unusually Large Options Volume (NASDAQ:SIGA)

August 7, 2025 | marketbeat.com

Siga Technologies (NASDAQ:SIGA) Issues Earnings Results

August 6, 2025 | marketbeat.com

SIGA Technologies (SIGA) Reports Significant Earnings Decline

August 6, 2025 | finance.yahoo.com

SIGA advances pediatric and PEP programs as product revenues reach $79M, supported by new BARDA funding

August 6, 2025 | msn.com

SIGA Technologies, Inc. (SIGA) Q2 2025 Earnings Call Transcript

August 6, 2025 | seekingalpha.com

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025

August 5, 2025 | globenewswire.com

SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results

July 29, 2025 | globenewswire.com

Royce & Associates LP Has $4.16 Million Holdings in Siga Technologies Inc. (NASDAQ:SIGA)

July 28, 2025 | marketbeat.com

Siga Technologies Inc. (SIGA) Stock Falls Amid Market Uptick: What Investors Need to Know

July 24, 2025 | zacks.com

Traders Buy Large Volume of Call Options on Siga Technologies (NASDAQ:SIGA)

July 24, 2025 | marketbeat.com

Siga Technologies Inc. (SIGA) Dips More Than Broader Market: What You Should Know

July 15, 2025 | msn.com

US Market's Undiscovered Gems Featuring Three Promising Small Caps

July 15, 2025 | finance.yahoo.com

Siga Technologies Inc. (SIGA) Laps the Stock Market: Here's Why

July 9, 2025 | zacks.com

SIGA Technologies Inc Dividends - Morningstar

July 8, 2025 | morningstar.comM

Why Siga Technologies Inc. (SIGA) Outpaced the Stock Market Today

June 26, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ANL, AKBA, SIGA, and AEON Company Descriptions

AEON Biopharma NASDAQ:AEON

$0.77 -0.01 (-1.54%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$0.79 +0.02 (+2.99%)

As of 08/15/2025 07:50 PM Eastern

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

Akebia Therapeutics NASDAQ:AKBA

$3.25 -0.04 (-1.22%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$3.22 -0.03 (-0.92%)

As of 08/15/2025 08:00 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Adlai Nortye NASDAQ:ANL

$1.69 -0.06 (-3.43%)

Closing price 08/15/2025 03:56 PM Eastern

Extended Trading

$1.74 +0.05 (+2.66%)

As of 08/15/2025 05:41 PM Eastern

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Siga Technologies NASDAQ:SIGA

$8.50 -0.08 (-0.93%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$8.50 0.00 (0.00%)

As of 08/15/2025 07:54 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time